Tonix (TNXP) upsizes ATM common stock offering to $400M
Tonix Pharmaceuticals (TNXP) is updating its at-the-market common stock offering program under its existing Sales Agreement with A.G.P./Alliance Global Partners.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals (TNXP) is updating its at-the-market common stock offering program under its existing Sales Agreement with A.G.P./Alliance Global Partners. The company is now offering up to an aggregate of $400,000,000 of its common stock under this program.
Under the prior prospectus, Tonix had registered up to $150,000,000 and sold 3,882,223 shares of common stock for an aggregate purchase price of $103.1 million. Following this prospectus supplement dated November 21, 2025, Tonix may sell up to an additional $296.9 million of common stock under the Sales Agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule
424(b)(5)
Registration No. 333-282270
Registration No. 333-287965
PROSPECTUS SUPPLEMENT
(To Prospectuses Dated September 30, 2024, and September 4, 2025)
$250,000,000
Common Stock
This prospectus supplement amends and supplements the information in the prospectus, dated June 11, 2025, filed as a part of our registration statement on Form S-3 (File No. 333-282270) (the “Prior Prospectus”), and the prospectus, dated September 4, 2025, filed as part of our Registration Statement on Form S-3 (File No. 333-287965) (together with the Prior Prospectus, the “Prospectuses”). This prospectus supplement should be read in conjunction with the Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectuses. This prospectus supplement is not complete without and may only be delivered or utilized in connection with, the Prospectuses, and any future amendments or supplements thereto.
Under the Prior Prospectus, we registered up to an aggregate of $150,000,000 of our common stock, $0.001 par value per share, for offer and sale pursuant to a Sales Agreement, dated June 11, 2025, as amended on November 21, 2025, or the Sales Agreement, between us and A.G.P./Alliance Global Partners. From June 11, 2025 through the date of this prospectus supplement, we sold an aggregate of 3,882,223 shares of our Common Stock, for an aggregate purchase price of $103.1 million under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $400,000,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold, or $296.9 million from and after the date hereof.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
A.G.P.
The date of this prospectus supplement is November 21, 2025.